Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harpoon Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harpoon Therapeutics's position in the market.
Seismic Therapeutic, a machine learning immunology company, has appointed Julie Eastland as an Independent Director to its Board. Ms. Eastland brings over 30 years of experience in finance and strategy within clinical stage biotechnology companies. Her expertise spans the drug development process, from discovery to commercialization, particularly in oncology and immunology.
Ms. Eastland most recently served as CEO and Board Director of Harpoon Therapeutics (HARP), which was acquired by Merck & Co in March 2024. She has held various C-level executive roles in both private and public companies, including ReCode Therapeutics, Rainier Therapeutics, and Cascadian Therapeutics. Her experience includes guiding biotechnology companies through significant organizational growth and navigating financial and operational challenges.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.